Dive into the archives.
- If caught early, Tysabri-PML not fatal for MS patients
Alexandra Schroder, M.D., the lead investigator from Ruhr-University in Bochum, Germany points out that this is different for those who don’t have multiple sclerosis (MS) and get PML. PML, progressive multifocal leukoencephalopathy, is a rare, always serious and often fatal disease that damages the white matter of the brain at multiple locations. It is caused [...]
- EX-US: First Oral Approved for PWMS: Cladribine approved in RUSSIA
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the Russian Federal Service on Surveillance in Healthcare and Social Development has become the first government agency to grant marketing approval to Cladribine Tablets for the treatment of relapsing-remitting multiple sclerosis (MS). Cladribine Tablets will be available in Russia under the trade name [...]
- Sativex Launched in UK
LONDON—A drug manufactured from cannabis went on sale in the U.K. Monday as a treatment for symptoms of multiple sclerosis. Sativex, which is made from cannabis plants grown at secret locations in England by developer GW Pharmaceuticals PLC, is the first prescription drug made from cannabis to officially go on sale anywhere in the world. [...]
- Cannabis spray approved in Britain to relieve spasticity in PWMS
LONDON, June 18 (Reuters) – GW Pharmaceuticals Plc’s (GWP.L) cannabis-derived medicine Sativex has been approved in Britain for treating spasticity in patients with multiple sclerosis, in a landmark decision for the small drugmaker. The much-delayed product was finally granted a British licence on Thursday, an official from the Medicines and Healthcare products Regulatory Agency (MHRA) [...]
- Newly Published Data Show Copaxone Promoted Remyelination of Damaged Axons
The purpose of this study was to examine the effect of glatiramer acetate on oligodendrogenesis (the formation of myelin-producing glial cells in the central nervous system) and myelin formation in damaged nerve cells in mice The mice were subjected to lysolecithin-induced demyelination of the spinal cord, then treated daily for seven days with a 2mg [...]
